A number of different measures can be used within cost-utility analyses, we compared results according to both the EQ-5D and SF-6D.
A randomized trial was conducted to compare 4 options for people with knee pain. Over the 2 year trial period, the change in cost to health-service was estimated, and both the EQ-5D and SF-6D were used to estimate the change in quality-adjusted life years (QALYs). Using a complete case analysis, the cost-utility (incremental cost-effectiveness ratio [ICER]) of each option, according to both the EQ-5D and SF-6D, was calculated and assessed in relation to the cost-effectiveness threshold of £20,000 per QALY.
Of the 389 participants, 247 had complete cost, EQ-5D and SF-6D data. According to the EQ-5D, option 1 had an estimated ICER of £10,815 (compared with option 4), option 2 was dominated by option 1, and option 3 was subject to extended dominance. Conversely, according to the SF-6D, option 3 had an ICER of £9999 (compared with option 4), option 2 had an ICER of £36,883 (compared with option 3), and option 1 was subject to extended dominance.
The EQ-5D and SF-6D estimated that different options (1 and 3, respectively) were cost-effective at the £20,000 per QALY threshold, demonstrating that the choice of measure does matter.
From the *School of Chemical Sciences and Pharmacy, University of East Anglia, Norwich, United Kingdom; †Health Economics Group, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, United Kingdom; ‡School of Community Health Sciences, University of Nottingham, Nottingham, United Kingdom; and §Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom.
The LIKP study was supported by the UK Arthritis Research Campaign (ARC) grant (13550).
Reprints: Garry Barton, PhD, Lecturer in Health Economics, Health Economics Group, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, NR4 7TJ, United Kingdom. E-mail: email@example.com.